CEN BIOTECH INC (CENB) financial statements (2021 and earlier)
Company profile
| Business Address |
300-3295 QUALITY WAY WINDSOR, ON N8T 3R9 |
| State of Incorp. | |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | |||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash, cash equivalents, and short-term investments | 2 | 4 | 3 | 85 | 62 | 3 | ||
| Cash and cash equivalents | 2 | 4 | 3 | 85 | 62 | 3 | ||
| Receivables | 18 | |||||||
| Total current assets: | 20 | 4 | 3 | 85 | 62 | 3 | ||
| Noncurrent Assets | ||||||||
| Operating lease, right-of-use asset | 229 | ✕ | ✕ | ✕ | ✕ | |||
| Property, plant and equipment | 148 | 167 | 15 | 16 | 8,292 | |||
| Long-term investments and receivables | 1,224 | 1,110 | 45 | 45 | ||||
| Due from related parties | 1,224 | 1,110 | 45 | 45 | ||||
| Intangible assets, net (including goodwill) | 4,956 | 5,381 | 5,806 | 6,231 | 2,320 | |||
| Intangible assets, net (excluding goodwill) | 4,956 | 5,381 | 5,806 | 6,231 | 2,320 | |||
| Deferred costs | 217 | |||||||
| Other undisclosed noncurrent assets | 114 | 1,695 | ||||||
| Total noncurrent assets: | 6,294 | 6,869 | 6,017 | 6,507 | 4,032 | 8,292 | ||
| Other undisclosed assets | 424 | 1,294 | 2,429 | |||||
| TOTAL ASSETS: | 6,314 | 7,296 | 7,315 | 9,021 | 4,094 | 8,295 | ||
| LIABILITIES AND EQUITY | ||||||||
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued liabilities | 1,957 | 10,341 | 7,469 | 4,929 | 3,715 | 1,986 | ||
| Accounts payable | 191 | 181 | 207 | 93 | 157 | 165 | ||
| Accrued liabilities | 641 | 575 | 402 | 296 | 841 | 594 | ||
| Interest and dividends payable | 1,125 | 9,585 | 6,860 | 4,541 | 2,717 | 1,228 | ||
| Debt | 7,707 | 15,307 | 13,705 | 11,444 | 19,925 | 9,866 | ||
| Due to related parties | 1,372 | 1,363 | 1,361 | 12 | 63 | 75 | ||
| Other undisclosed current liabilities | 3,670 | 3,858 | 1,873 | 3,642 | (9,009) | 1,564 | ||
| Total current liabilities: | 14,706 | 30,868 | 24,408 | 20,027 | 14,694 | 13,491 | ||
| Noncurrent Liabilities | ||||||||
| Long-term debt and lease obligation | 220 | 1,223 | 1,546 | 2,208 | 1,392 | |||
| Long-term debt, excluding current maturities | 78 | 1,039 | 1,546 | 2,208 | 1,392 | |||
| Operating lease, liability | 142 | 184 | ✕ | ✕ | ✕ | ✕ | ||
| Liabilities, other than long-term debt | 300 | |||||||
| Due to related parties | 300 | |||||||
| Other undisclosed noncurrent liabilities | 1,238 | 556 | 2,622 | 5,500 | 1,388 | 612 | ||
| Total noncurrent liabilities: | 1,600 | 1,963 | 4,168 | 8,008 | 2,780 | 612 | ||
| Total liabilities: | 16,306 | 32,832 | 28,576 | 28,036 | 17,474 | 14,103 | ||
| Stockholders' equity | ||||||||
| Stockholders' equity attributable to parent, including: | (9,992) | (25,535) | (21,261) | (19,015) | (13,390) | (5,808) | ||
| Preferred stock | 0 | 0 | ||||||
| Common stock | 0 | 0 | ||||||
| Additional paid in capital | 17,069 | 15,775 | 14,394 | 9,110 | 10 | |||
| Accumulated deficit | (27,061) | (41,310) | (35,655) | (28,125) | (13,390) | (5,808) | ||
| Other undisclosed stockholders' equity attributable to parent | (10) | |||||||
| Other undisclosed stockholders' equity | 10 | |||||||
| Total stockholders' equity: | (9,992) | (25,535) | (21,261) | (19,015) | (13,380) | (5,808) | ||
| TOTAL LIABILITIES AND EQUITY: | 6,314 | 7,296 | 7,315 | 9,021 | 4,094 | 8,295 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Gross profit: | 2 | ||||||
| Operating expenses | (2,544) | (2,580) | (4,371) | (11,614) | (5,981) | (1,166) | |
| Other undisclosed operating loss | (2) | ||||||
| Operating loss: | (2,544) | (2,580) | (4,371) | (11,614) | (5,981) | (1,166) | |
| Nonoperating income (expense) | 16,793 | (3,075) | (3,160) | (2,466) | (1,601) | (121) | |
| Foreign currency transaction gain (loss), before tax | (55) | (66) | 92 | (89) | (48) | (121) | |
| Interest and debt expense | (443) | (450) | (431) | (336) | (288) | (1,362) | |
| Net income (loss): | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | (2,649) | |
| Other undisclosed net income attributable to parent | 443 | 450 | 431 | 336 | 288 | 242 | |
| Net income (loss) available to common stockholders, basic: | 14,250 | (5,655) | (7,530) | (14,080) | (7,582) | (2,407) | |
| Dilutive securities, effect on basic earnings per share | 585 | ||||||
| Net income (loss) available to common stockholders, diluted: | 14,835 | (5,655) | (7,530) | (14,080) | (7,582) | (2,407) | |
Comprehensive Income ($ in thousands)
| 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | ||
|---|---|---|---|---|---|---|---|
| Net income (loss): | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | (2,649) | |
| Comprehensive income (loss), net of tax, attributable to parent: | 13,806 | (6,105) | (7,961) | (14,417) | (7,870) | (2,649) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.